FindMyKOL
Clinical trialNCT04584255Active, not recruitingPhase 2Interventional

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

SponsorDana-Farber Cancer InstituteEnrollment62Breast CancerDeleterious PALB2 Gene MutationGermline BRCA1 Gene MutationGermline BRCA2 Gene MutationHER2-negative Breast CancerStage I Breast Cancer+2 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research study involves pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA and PALB2 mutations. The names of the study drugs involved in this study are: * Niraparib (Zejula) * Dostarlimab
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Yale University Cancer Center

    New Haven, Connecticut, United States

  • Johns Hopkins University

    Baltimore, Maryland, United States

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, United States

  • Mayo Clinic

    Rochester, Minnesota, United States

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee, United States

  • University of Washington / Fred Hutchinson Cancer Center

    Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Dostarlimab →Niraparib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
18 Dec 2020
Primary completion
1 Jul 2025
Completion
17 Jul 2029
Last update posted
13 May 2026
Registered enrollment
62
Registry id
NCT04584255
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.